Loading...
•
Dec 31, 2025
MacroGenics Q4 2025 Earnings Report
MacroGenics reported strong Q4 revenue driven by collaboration and contract manufacturing activity, returning to profitability after losses earlier in the year.
Key Takeaways
MacroGenics generated significant collaboration and manufacturing revenue in Q4 2025, leading to positive operating income and net income following losses earlier in the year. The quarter reflected milestone and collaboration payments as well as increased contract manufacturing activity.
Q4 revenue was approximately 41227000 calculated from full-year results after strong earlier collaboration revenue.
The company generated positive operating income and net income in the fourth quarter.
Contract manufacturing and collaboration agreements continued to drive the majority of revenue.
MacroGenics ended the year with a strong balance sheet and significant cash reserves to fund development.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
MacroGenics expects continued investment in its oncology pipeline and expects its cash position to support development programs and operations into the coming years.
Positive Outlook
- Strong collaboration relationships with major pharmaceutical partners.
- Multiple clinical catalysts expected from ADC and DART programs.
- Contract manufacturing operations generate recurring revenue.
- Significant cash reserves provide funding runway.
- Potential milestone and royalty payments from partners.
Challenges Ahead
- Revenue remains highly dependent on milestone and collaboration payments.
- Pipeline development requires substantial R&D spending.
- Commercial product revenue is currently limited.
- Future results depend on clinical and regulatory outcomes.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...